Hologic (NASDAQ:HOLX) had its target price lifted by Argus to $62.00 in a research note published on Wednesday, The Fly reports. Argus currently has a buy rating on the medical equipment provider’s stock.
A number of other brokerages have also recently issued reports on HOLX. Canaccord Genuity reaffirmed a hold rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. BidaskClub raised shares of Hologic from a hold rating to a buy rating in a report on Saturday, July 27th. ValuEngine cut shares of Hologic from a buy rating to a hold rating in a report on Thursday, August 1st. BTIG Research reaffirmed a buy rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. Finally, TheStreet raised shares of Hologic from a c+ rating to a b rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. Hologic has a consensus rating of Hold and a consensus target price of $48.52.
Shares of NASDAQ:HOLX opened at $50.45 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 1.57 and a debt-to-equity ratio of 1.27. The company has a market cap of $13.32 billion, a P/E ratio of 22.62, a PEG ratio of 2.26 and a beta of 0.74. Hologic has a 52 week low of $37.47 and a 52 week high of $52.19. The company has a 50-day moving average price of $48.89 and a 200 day moving average price of $46.89.
In other Hologic news, insider Peter J. Valenti III sold 4,545 shares of Hologic stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $44.07, for a total value of $200,298.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $48.77, for a total transaction of $9,480,692.92. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. CWM LLC grew its stake in Hologic by 3,466.7% in the 2nd quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 520 shares during the period. Horan Capital Advisors LLC. purchased a new stake in Hologic in the 1st quarter worth approximately $33,000. First Interstate Bank purchased a new stake in Hologic in the 1st quarter worth approximately $40,000. CSat Investment Advisory L.P. grew its stake in Hologic by 66.9% in the 2nd quarter. CSat Investment Advisory L.P. now owns 831 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 333 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in Hologic by 1,363.2% in the 1st quarter. Quadrant Capital Group LLC now owns 995 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 927 shares during the period. 96.43% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.